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Dear Editor,
In December 2009, a 43-year-old,
mechanically ventilated patient with
acute respiratory distress syndrome
(ARDS) due to A(H1N1) influenza
infection was transferred to our
intensive care unit (ICU) for extra-
corporal membrane oxygenation.
Prior to admission to the first hospital,
the patient had been in good health;
his personal history was unremark-
able, except for obesity (body mass
index 41 kg/m2) and a borderline
personality disorder with intermittent
alcohol abuse. The A(H1N1) infec-
tion resolved following treatment
with oseltamivirr; however, his clini-
cal condition subsequently worsened
again, characterized by severe hemo-
dynamic impairment with excessive
need for vasoactive compounds,
including norepinephrine (up to 90
g/min) and vasopressin (up to 0.04
U/min). Bacterial sepsis was excluded
based on repetitive negative blood
cultures. Sharply demarcated ery-
thematous skin lesions developed
simultaneously on the trunk, arms,
and legs (Fig. 1a). Differential diag-
nosis included allergic reaction to
several medications, eosinophilic
cellulitis (Muckle–Wells’ syndrome),
and small-vessel vasculitis or infec-
tious vasculitis.
Laboratory evaluation showed
peripheral eosinophilia, thrombocy-
topenia, and progredient liver failure;
alanine aminotransferase was 105 U/l,
the international normalized ratio was
2.0, and the production of both albu-
min and coagulation factors was
reduced (albumin 14 g/l; factor V
39%, II 39%, VII 23%). Viral RNA
for novel influenza A(H1N1) was no
longer detectable in nasal and pha-
ryngeal swabs. Serologic testing for
hepatitis B and C and autoimmune
antibodies, including anti-smooth
muscle (anti-Sm) and antimitochond-
rial (AMA) antibodies, were negative.
PCR assay results for herpes simplex
type 1 and 2, varicella zoster,
Epstein–Barr virus, and human herpes
virus 6 were also negative. However,
the PCR assay was positive for CMV,
detecting viral loads up to a level of 5
million copies per milliliter. Skin
biopsies were performed and showed
discrete lymphocytic inflammation
and characteristic nuclear inclusion
bodies [1] within the vascular endo-
thelial cells (‘‘owl’s eyes’’; Fig. 1b).
CMV infection of the vessels was
confirmed by PCR. Antiviral treat-
ment with ganciclovir was initiated,
and the rash disappeared promptly,
allowing the amount of vasoactive
pressors to be reduced. Forty-seven
days after the initiation of antiviral
therapy, viral loads were no longer
detectable by PCR.
Infections with CMV, a member of
the herpesvirus family with high
seroprevalence in the adult popula-
tion, are of major concern in neonates
and in patients with significant
immunosuppression, in particular in
those with acquired immune defi-
ciency syndrome (AIDS) and
transplant recipients. Both de novo
infection and reactivation of the latent
state of the virus usually lead to
severe illness in these patients,
whereas clinically apparent disease
does not occur in the vast majority of
infections in immunocompetent hosts.
Common organ-specific complica-
tions of CMV infection include liver
function abnormalities, gastrointesti-
nal manifestations, Guillan–Barre´
syndrome, pneumonitis, and retinitis.
Moreover, reactivation of CMV
infection is commonly observed in
critically ill patients and is associated
with disease severity, prolonged hos-
pitalization in the ICU, and mortality
Fig. 1 a Erythematous, macu-
lar rash, sharply demarcated
within hypopigmented areas.
b Skin biopsy samples revealing
discrete lymphocytic infiltration
surrounding the perivascular tis-
sue; cytomegalovirus (CMV)-
specific inclusion bodies within
vascular endothelial cells
(arrow) presenting as character-
istic ‘‘owl’s eyes’’ (inset)
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[2, 3]. Cutaneous manifestations,
however, appear to be rare clinical
entities [4, 5]. Our case thus illus-
trates the importance of recognizing
and treating CMV infection in non-
immunosuppressed patients in the
ICU, in particular in those with
unexplained rash.
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